HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Incidence of neutropenia in patients with ticlopidine/Ginkgo biloba extract combination drug for vascular events: A post-marketing cohort study.

AbstractBACKGROUND AND PURPOSE:
The ticlopidine/Ginkgo biloba ext. combination drug (Yuclid) is used as an antiplatelet agent for prevention of vascular events since its approval in 2008. The purpose of this study is to explore the safety of ticlopidine/Ginkgo biloba combination, mainly regarding the incidence of neutropenia, through a post-marketing surveillance study.
METHODS:
From March 2009 to October 2015, a total of 4839 subjects had been enrolled in this study. The enrollments were conducted by 152 doctors of 89 hospitals according to the regulations for post-marketing surveillance programs in Korea. If a subject was administered the drug once, he/she was included in the safety analysis set for any adverse events and bleedings, and the primary safety evaluation regarding neutropenia was conducted in subjects who completed 3-month blood test follow-up. We predefined that 1% reduction in neutropenia incidence by ticlopidine/Ginkgo biloba ext. combination from the previously reported incidence of ticlopidine of 2.3% was clinically meaningful.
RESULTS:
Among the safety analysis set of 4831 patients (99.8% of the enrolled subjects), 3150 (65.1%) completed evaluation for neutropenia at 3 months which is the primary safety endpoint. The major causes of dropout were no follow-up visit at 3 months (n = 1016) and violation of the follow-up period (n = 503). Nine patients experienced neutropenia (Absolute neutrophil count [ANC] ≤ 1200mm3) and the estimated cumulative incidence at 3 months is 0.29% (95% confidence interval, 0.13%- 0.54%). Severe neutropenia (ANC ≤ 450mm3) did not occur in any patients.
CONCLUSIONS:
The incidence of neutropenia with addition of Ginkgo biloba ext. to ticlopidine may be lower than the previously reported incidence of neutropenia with ticlopidine, which needs to be confirmed in randomized controlled trials.
AuthorsHan-Gil Jeong, Jae Sun Yoon, Juneyoung Lee, Hee-Joon Bae
JournalPloS one (PLoS One) Vol. 14 Issue 6 Pg. e0217723 ( 2019) ISSN: 1932-6203 [Electronic] United States
PMID31166961 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Drug Combinations
  • Plant Extracts
  • Ginkgo biloba extract
  • Ticlopidine
Topics
  • Aged
  • Cohort Studies
  • Drug Combinations
  • Female
  • Ginkgo biloba
  • Hemorrhage (chemically induced, epidemiology)
  • Humans
  • Incidence
  • Male
  • Meta-Analysis as Topic
  • Neutropenia (chemically induced, epidemiology)
  • Plant Extracts (adverse effects, therapeutic use)
  • Product Surveillance, Postmarketing
  • Republic of Korea (epidemiology)
  • Ticlopidine (adverse effects, therapeutic use)
  • Vascular Diseases (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: